<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26640412</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of biological sciences</Title><ISOAbbreviation>Int J Biol Sci</ISOAbbreviation></Journal><ArticleTitle>Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0.</ArticleTitle><Pagination><StartPage>1337</StartPage><EndPage>1347</EndPage><MedlinePgn>1337-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijbs.12996</ELocationID><Abstract><AbstractText>In recent years, hand-foot-and-mouth disease (HFMD), which is caused by Enteroviruses, has emerged as a serious illness. It affects mainly children under the age of five and results in high fatality rates. Enterovirus 71 (EV71) is the main causative agent of HFMD in China and currently there are no effective anti-viral drugs available to treat HFMD. In the present study, we screened compounds for inhibition of proliferation of EV71. Compound YZ-LY-0 stalled the life cycle of EV71. The inhibitor exhibited EC50 value of 0.29 &#x3bc;m against SK-EV006 strain of EV71. Notably, YZ-LY-0 had low cytotoxicity (CC50 &gt; 100 &#x3bc;M) and a high selectivity index (over 300) in Vero and RD cells. YZ-LY-0 in combination with an EV71 RdRp inhibitor or an entry inhibitor showed an antagonistic effect at very low concentrations. However, at higher concentrations the inhibitors exhibited a synergistic effect in inhibiting viral replication. Preliminary results on investigation of the mechanism of inhibition indicate that YZ-LY-0 does not block the entry of the virus in the host cell, but instead inhibits an early stage of EV71 replication. Our studies provide a potential clinical therapeutic option against EV71 infections and suggest that a combined application of YZ-LY-0 with other inhibitors could be more effective in the treatment of HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingzhan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1. School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jie</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>2. Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1. School of Medicine, Tsinghua University, Beijing 100084, China ; 3. National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>5. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Zihe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1. School of Medicine, Tsinghua University, Beijing 100084, China ; 3. National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China ; 5. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>4. College of Pharmacy &amp; State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China; Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Zhiyong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1. School of Medicine, Tsinghua University, Beijing 100084, China ; 5. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Biol Sci</MedlineTA><NlmUniqueID>101235568</NlmUniqueID><ISSNLinking>1449-2288</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">inhibitor</Keyword><Keyword MajorTopicYN="N">mechanism</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26640412</ArticleId><ArticleId IdType="pmc">PMC4643065</ArticleId><ArticleId IdType="doi">10.7150/ijbs.12996</ArticleId><ArticleId IdType="pii">ijbsv11p1337</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen T-C, Chang H-Y, Lin P-F, Chern J-H, Hsu JT-A, Chang C-Y. et al. Novel Antiviral Agent DTriP-22 Targets RNA-Dependent RNA Polymerase of Enterovirus 71. Antimicrobial Agents And Chemotherapy. 2009;53:2740&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Chang YC, Huang CC, Lui CC, Lee KW, Huang SC. Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. American Journal Of Neuroradiology. 2001;22:200&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7975539</ArticleId><ArticleId IdType="pubmed">11158910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Feng Z, Yang Y, Self S, Gao Y, Longini IM. et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22:781&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246273</ArticleId><ArticleId IdType="pubmed">21968769</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CL, Chu EY, Introcaso CE, Schaffer A, James WD. Coxsackievirus A6-Induced Hand-Foot-Mouth Diseasee. Jama Dermatology. 2013;149:1419&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24172861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng ZM, Zhang J, Zhu W, He P. First isolation of enterovirus type 71 from vesicle fluid of an adult patient with hand-foot-mouth disease in China. Virologica Sinica. 1989;4:375&#x2013;82.</Citation></Reference><Reference><Citation>Yang Y, Wang H, Gong E, Du J, Zhao X, McNutt MA. et al. Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People's Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study. Human pathology. 2009;40:1288&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">19386354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y. et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virology journal. 2010;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. The Pediatric infectious disease journal. 2004;23:275&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wang Y, Shan C, Chen C, Xu P, Song M. et al. Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase. Journal of virology. 2012;86:13662&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503026</ArticleId><ArticleId IdType="pubmed">23055549</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS microbiology reviews. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. Journal of virology. 2000;74:10359&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110910</ArticleId><ArticleId IdType="pubmed">11044080</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamarnik AV, Andino R. Switch from translation to RNA replication in a positive-stranded RNA virus. Genes &amp; development. 1998;12:2293&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317040</ArticleId><ArticleId IdType="pubmed">9694795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman BI, Foglia R, Yuan W. Satellite and defective RNAs of Cryphonectria hypovirus 3-grand haven 2, a virus species in the family Hypoviridae with a single open reading frame. Virology. 2000;276:181&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11022006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988;334:320&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2839775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang Y, Shan C, Sun Y, Xu P, Zhou H. et al. Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation. Journal of virology. 2013;87:5755&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648134</ArticleId><ArticleId IdType="pubmed">23487447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Guo Y, Lou Z. Formation and working mechanism of the picornavirus VPg uridylylation complex. Current opinion in virology. 2014;9:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">25240314</ArticleId></ArticleIdList></Reference><Reference><Citation>Steil BP, Kempf BJ, Barton DJ. Poly(A) at the 3 ' End of Positive-Strand RNA and VPg-Linked Poly(U) at the 5 ' End of Negative-Strand RNA Are Reciprocal Templates during Replication of Poliovirus RNA. Journal of virology. 2010;84:2843&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826026</ArticleId><ArticleId IdType="pubmed">20071574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R. et al. Enterovirus 71 Outbreak in the People's Republic of China in 2008. Journal Of Clinical Microbiology. 2009;47:2351&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY. et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Xu M, Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral research. 2013;97:183&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T-C, Weng K-F, Chang S-C, Lin J-Y, Huang P-N, Shih S-R. Development of antiviral agents for enteroviruses. Journal Of Antimicrobial Chemotherapy. 2008;62:1169&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931391</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P. et al. Inhibition of enterovirus 71 by adenosine analog NITD008. Journal of virology. 2014;88:11915&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Wang Y, Qing J, Shu B, Cao L, Lou Z. et al. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral research. 2014;112:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorganic &amp; medicinal chemistry letters. 2002;12:733&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11858991</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P. et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014;58:6990&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Spyrou JA, Kelly J, Ren J, Grimes J. et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nature structural &amp; molecular biology. 2014;21:282&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J. et al. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS pathogens. 2014;10:e1004422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X. et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerging microbes &amp; infections. 2014;3:e62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y. et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. The Journal of biological chemistry. 2012;287:6406&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008;3:1101&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral research. 1990;14:181&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">2088205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T. et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature medicine. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y. et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. The Journal of biological chemistry. 2012;287:6406&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z-H, Li C-M, Ling P, Shen F-H, Chen S-H, Liu C-C. et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. Journal Of Infectious Diseases. 2008;197:854&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoll J, Heus HA, van Kuppeveld FJM, Melchers WJG. The structure-function relationship of the enterovirus 3 '-UTR. Virus Research. 2009;139:209&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18706945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic vaccines and therapy. 2007;5:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>